EMA Authorised: Incruse Ellipta (previously Incruse) (umeclidinium bromide) — GlaxoSmithKline Trading Services Limited

View source ↗

Summary

The EMA has authorised Incruse Ellipta, a umeclidinium bromide inhaler, for chronic obstructive pulmonary disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Incruse Ellipta (umeclidinium bromide)

Snippet

Status: Authorised. Therapeutic area: Pulmonary Disease, Chronic Obstructive. MAH: GlaxoSmithKline Trading Services Limited. Decision date: 17/07/2025